Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regorafenib.

Thomas J Ettrich1, Thomas Seufferlein2

  • 1Department of Internal Medicine I, University of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Frequencies and Screening in Individuals With Down Syndrome: A Comprehensive Nationwide Cross-Sectional Analysis.

JCO global oncology·2026
Same author

Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach.

Gastroenterology research·2026
Same author

Safety and preliminary activity of neoadjuvant trastuzumab deruxtecan (T-DXd) plus 5-fluorouracil and folinic acid for HER2-positive, resectable esophagogastric adenocarcinoma: Results from the safety run-in cohort of the phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART trial.

Oncology research and treatment·2026
Same author

ATM Deficiency Induces TGF-β-Mediated Stromal Programming in Pancreatic Cancer.

Cancer research·2026
Same author

[Prevention in Gastroenterology].

Zeitschrift fur Gastroenterologie·2026
Same author

A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.

Scientific reports·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Regorafenib, a multi-kinase inhibitor, offers survival benefits for patients with advanced metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. It targets key kinases involved in tumor growth and angiogenesis.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Regorafenib is an oral multi-kinase inhibitor targeting angiogenic, stromal, and oncogenic receptor tyrosine kinases.
  • It represents a significant advancement in small-molecule targeted therapies for various cancers.

Purpose of the Study:

  • To review the efficacy and FDA approvals of Regorafenib in specific cancer indications.
  • To highlight its role in treating refractory metastatic colorectal cancer, gastrointestinal stromal tumors, and advanced hepatocellular carcinoma.

Main Methods:

  • Review of clinical trial data and FDA approval history for Regorafenib.
  • Analysis of Regorafenib's mechanism of action as a multi-kinase inhibitor.

Main Results:

Keywords:
CRCGISTHCCRegorafenibTKI

Related Experiment Videos

  • Regorafenib demonstrated survival benefits in metastatic colorectal cancer, leading to FDA approval in 2012.
  • Significant improvement in progression-free survival (PFS) was observed in metastatic gastrointestinal stromal tumors (GIST) and advanced hepatocellular carcinoma (HCC).
  • Regorafenib is FDA-approved for GIST (2013) and HCC (2017) after prior treatments.

Conclusions:

  • Regorafenib is an effective therapeutic option for patients with refractory metastatic colorectal cancer, GIST, and HCC.
  • Ongoing trials are exploring its utility in other tumor types like renal cell carcinoma and soft-tissue sarcoma.